Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: How circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment

Drug Metabolism and Disposition

Volumn 39, Issue 1, 2011, Pages 123-131

  Zhang, Donglu ^a   Raghavan, Nirmala ^a   Wang, Lifei ^a   Xue, Yongjun ^a   Obermeier, Mary ^a   Chen, Stephanie ^a   Tao, Shiwei ^a   Zhang, Hao ^a   Cheng, Peter T ^a   Li, Wenying ^a   Ramanathan, Ragu ^a   Yang, Zheng ^a   Griffith Humphreys, W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 O ACYL ALPHA GLUCURONIDE; DRUG METABOLITE; GLUCURONIDE; MURAGLITAZAR; MURAGLITAZAR ACYL GLUCURONIDE; PELIGLITAZAR; PELIGLITAZAR ACYL GLUCURONIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG STABILITY; GLUCURONIDATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; LIVER CELL; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT;

ADULT; ANIMALS; BILE; DRUG STABILITY; GLUCURONIDES; GLYCINE; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICROSOMES, LIVER; OXAZOLES; OXIDATION-REDUCTION; PPAR ALPHA; PPAR GAMMA; RATS; RISK ASSESSMENT; URIDINE DIPHOSPHATE GLUCURONIC ACID; YOUNG ADULT;

ANIMALIA; RATTUS;

EID: 78650736079     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035048     Document Type: Article

References (29)

1. Akira K, Hasegawa H, Shinohara Y, Imachi M, and Hashimoto T (2000) Stereoselective internal acyl migration of 1β-O-acyl glucuronides of enantiomeric 2-phenylpropionic acids. Biol Pharm Bull 23: 506-510.
2. Akira K, Uchijima T, and Hashimoto T (2002) Rapid internal acyl migration and protein binding of synthetic probenecid glucuronides. Chem Res Toxicol 15: 765-772.
3. Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145:117-137.
4. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
5. Corcoran O, Mortensen RW, Hansen SH, Troke J, and Nicholson JK (2001) HPLC/1H NMR spectroscopic studies of the reactive α-1-O-acyl isomer formed during acyl migration of S-naproxen β-1-O-acyl glucuronide. Chem Res Toxicol 14:1363-1370.
6. Ebner T, Heinzel G, Prox A, Beschke K, and Wachsmuth H (1999) Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos 27:1143-1149.
7. Ebner T, Wagner K, and Wienen W (2010) Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos 38:1567-1575.
8. Fenselau C (1994) Acyl glucuronides as chemically reactive intermediates, in Conjugation- Deconjugation Reactions in Drug Metabolism and Toxicity (Kaufmann FC ed) pp 367-374, Springer-Verlag, Berlin.
9. Hasegawa H, Akira K, Shinohara Y, Kasuya Y, and Hashimoto T (2001) Kinetics of intramolecular acyl migration of 1β-O-acyl glucuronides of (R)- and (S)-2-phenylpropionic acids. Biol Pharm Bull 24: 852-855.
10. Humphreys WG and Unger SE (2006) Safety assessment of drug metabolites: Characterization of chemically stable metabolites. Chem Res Toxicol 19:1564-1569.
11. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
12. Kenny JR, Maggs JL, Meng X, Sinnott D, Clarke SE, Park BK, and Stachulski AV (2004) Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac. J Med Chem 47:2816-2825.
13. Kochansky CJ, Xia YQ, Wang S, Cato B, Creighton M, Vincent SH, Franklin RB, and Reed JR (2005) Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide. Drug Metab Dispos 33:1894-1904.
14. Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH, Evans DC, and Baillie TA (2002) Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 303:969-978.
15. Mortensen RW, Corcoran O, Cornett C, Sidelmann UG, Troke J, Lindon JC, Nicholson JK, and Hansen SH (2001) LC-1H NMR used for determination of the elution order of S-naproxen glucuronide isomers in two isocratic reversed-phase LC-systems. J Pharm Biomed Anal 24:477-485.
16. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
17. Perrie JA, Harding JR, Holt DW, Johnston A, Meath P, and Stachulski AV (2005) Effective synthesis of 1-β-acyl glucuronides by selective acylation. Org Lett 7:2591-2594.
18. Sallustio BC and Foster DJ (1995) Reactivity of gemfibrozil 1-O-β-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rat. Drug Metab Dispos 23: 892-899.
19. Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5-47.
20. Stachulski AV, Harding JR, Lindon JC, Maggs JL, Park BK, and Wilson ID (2006) Acyl glucuronides: biological activity, chemical reactivity, and chemical synthesis. J Med Chem 49:6931-6945.
21. Shipkova M, Armstrong VW, Oellerich M, and Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1-16.
22. 14C-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection. Drug Metab Dispos 34:427-439.
23. 14C-labeled peliglitazar in humans. Drug Metab Dispos doi: 10.1124/dmd.110.035089.
24. Xue YJ, Akinsanya JB, Raghavan N, and Zhang D (2008) Optimization to eliminate the interference of migration isomers for measuring 1-O-β-acyl glucuronide without extensive chromatographic separation. Rapid Commun Mass Spectrom 22:109-120.
25. Zhang D, Hanson R, Roongta V, Dischino DD, Gao Q, Sloan CP, Polson C, Keavy D, Zheng M, Mitroka J, et al. (2006) In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor. Curr Drug Metab 7:883-896.
26. Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, and Klunk LJ (2005) Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled MaxiPost (BMS-204352) in humans. Drug Metab Dispos 33:83-93.
27. Zhang D, Raghavan N, Chando T, Gambardella J, Fu Y, Zhang D, Unger SE, and Humphreys WG (2007a) LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. Drug Metab Lett 1:293-298.
28. Zhang D, Wang L, Raghavan N, Zhang H, Li W, Cheng PT, Yao M, Zhang L, Zhu M, Bonacorsi S, et al. (2007b) Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. Drug Metab Dispos 35:150-167.
29. Zhu M, Zhang D, Zhang H, and Shyu WC (2009) Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations. Biopharm Drug Dispos 30:163-184.